Skip to main content

PBMs have outsized influence on U.S. drug prices due to market consolidation, FTC says

By Reuters  
   July 09, 2024

The FTC argues the three biggest PBMs - managing 79% of U.S. prescription drug claims - have greatly enriched themselves at the expense of smaller pharmacies and consumers, according to an interim staff report calling for possible greater regulation.

Full story

Get the latest on healthcare leadership in your inbox.